Realizing the hope.
Why?
Latest News
[18F]F-AraG in monitoring response and predicting outcomes in patients with cancer treated with PD-(L)1 therapy
December 6th, 2024
[18F]F-AraG’s ability to evaluate immune contexture within the tumor microenvironment as well as systemic immunity in patients with cancer treated with immunotherapy was presented at the 4th International congress on inflammation and infection imaging in Rome, Italy.
[18F]F-AraG uptake in the vertebral bone marrow predicts survival in immunotherapy treated non-small cell lung cancer patients
September 9th, 2024
The study by Dr. Levi et al. was recognized as one of the top abstracts at the 2024 WMIC in Montreal, Canada.
[18F]F-AraG reveals long-term immune system activation following COVID-19 infection
July 3rd, 2024
The USCF study by Peluso M.J. et al., which reported T cell activation and viral persistence in several tissues in post-acute COVID-19 participants, has made the cover of Science Translational Medicine, Volume 16, Issue 754.
[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue
June 10th, 2024
Collaborative project between CellSight, UCSF, UC Davis, Dana Farber and Stanford University that used 18F-AraG to demonstrate a connection between neuroinflammation and adipose tissue is presented at the SNMMI 2024 in Toronto.
Physiological Uptake of [18F]F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan
June 9th, 2024
At SNMMI in Toronto, Dr. Tomomi Nobashi from Kyoto University presented the first report on the use of 18F-AraG PET/CT in Asian population.
Emergence of novel CD3+ Macrophages in Brown Adipose Tissue Following Adrenergic Stimulation
May 5th, 2024
Dr. Hee-Don Chae reports on a unique population of CD3+F4/80+ dual lineage co-expressing cells within the interscapular brown adipose tissue that increased following chronic adrenergic stimulation.